IDRA Idera Pharmaceuticals, Inc.

1.67
-0.01  -1%
Previous Close 1.68
Open 1.72
Price To book 2.78
Market Cap 249.08M
Shares 149,148,000
Volume 522,348
Short Ratio 6.36
Av. Daily Volume 1,697,610

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 basket trial to be initiated 2H 2017.
IMO-2125
Cancer - solid tumors
Phase 2 arm enrolling. Overall response data due 1Q 2018.
IMO-2125
Cancer - melanoma
Development suspended - September 2016.
IMO-8400
Waldenström’s Macroglobulinemia
Development suspended - September 2016.
IMO-8400
Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 initiated November 2015. Enrollment to be completed by the end of 2017 with data due 1H 2018.
IMO-8400
Dermatomyositis

Latest News

  1. ETFs with exposure to Idera Pharmaceuticals, Inc. : May 22, 2017
  2. Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
  3. Idera Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IDRA) : May 5, 2017
  4. Here's Why Idera Pharmaceuticals, Inc. Is Sinking Today
  5. Idera reports 1Q loss
  6. Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
  7. Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IDRA-US : May 4, 2017
  8. The Market In 5 Minutes
  9. Today's Research Reports on Biotech Stocks to Watch: Idera Pharmaceuticals and ZIOPHARM Oncology
  10. Idera Pharmaceuticals Announces Organizational Update
  11. Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma
  12. Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting
  13. 3 Stocks the Smartest Investors are Buying Right Now
  14. ETFs with exposure to Idera Pharmaceuticals, Inc. : March 27, 2017
  15. 3 Stocks That Could Double Your Money
  16. Analyst Calls for Exponential Upside for Idera Pharmaceuticals
  17. Idera Pharmaceuticals and XOMA Find Paths to Financial Growth
  18. Idera Pharma Shares Could Be A Four-Bagger, JMP Says
  19. Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017